| Market Cap | $33.67M-97.7% |
| Revenue (ttm) | $2.58M |
| Net Income | -$342.52M |
| EPS | -$3.97 |
| Shares Out | 113.78M |
| PE Ratio | n/a |
| Forward PE | -0.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,575,241 |
| Open | $0.30 |
| Previous Close | $0.31 |
| Day's Range | $0.29 - $0.32 |
| 52-Week Range | $0.28 - $19.11 |
| Beta | 1.90 |
| Analysts | Hold |
| Price Target | $8.31(+2709.23%) |
| Earnings Date | Nov 12, 2026 |
About EYPT
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
8 firms rating EYPT in the last 3 months, one vote each. Issuer-paid research is not counted.
$EYPT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in EYPT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EYPT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EYPT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New EYPT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EYPT from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from EYPT’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings beat on revenue but company reported net loss and significant workforce reduction linked to Wet AMD setback, indicating material challenges ahead.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 0.07% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.04% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.02% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.01% |
| IHE | iShares U.S. Pharmaceuticals ETF | 0.01% |
| VHT | Vanguard Health Care ETF | 0.00% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.00% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.00% |
| FHLC | Fidelity MSCI Health Care Index ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
